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Antibodies against the CUB1-2 domains of
ADAMTS13 in a patient with benign monoclonal
gammopathy: no causal relationship
We present a patient with a history of benign
monoclonal gammopathy, who developed throm-
botic thrombocytopenic purpura (TTP), initially
presenting as bilateral serous retinal detachment.
Plasma of the patient contained high titers of anti-
ADAMTS13 antibodies that were directed
towards the disintegrin/TSR1/cysteine-rich/spacer
and CUB1-2 domains. ADAMTS13 activity was
undetectable. Total IgG purified from plasma of
the patient partially inhibited ADAMTS13 activity.
In contrast, the isolated M-protein did neither bind
to, nor inhibit activity of ADAMTS13. We con-
clude that in this patient the monoclonal gam-
mopathy and TTP co-existed as distinct patholog-
ical entities. Haematologica 2007; 92:(6)e74-e76
Idiopathic thrombotic thrombocytopenic purpura
(TTP) is a rare disorder associated with the presence of
unusually large von Willebrand factor (VWF) multimers in
plasma, which induce platelet aggregation and consump-
tion, tissue ischaemia, and microangiopathic haemolytic
anaemia.1 Unusually large VWF multimers arise as a con-
sequence of severely reduced activity of the VWF-cleaving
protease ADAMTS13 (a disintegrin and metalloprotease,
with thrombospondin-1-like domains).1 In most patients
with acquired TTP, antibodies directed to the cysteine-
rich/spacer domains of ADAMTS13 are present.2-5
In the current study, we describe a patient with a histo-
ry of benign monoclonal gammopathy who developed
TTP, and initially presented with bilateral serous retinal
detachment. We hypothesized that in this patient the
monoclonal immunoglobulin (M-protein) was directed
against ADAMTS13, and we conducted a series of in vitro
experiments to test this hypothesis.
Case report
A 43-year-old woman was referred to the department
of ophthalmology of our tertiary care university hospital.
She was known in a different hospital with chronic dis-
coid lupus erythematodes and monoclonal gammopathy
of undetermined significance (MGUS) for four years (most
recent values: lambda immunoglobulins 28 g/L, 2.2 % of
lambda monoclonal plasma cells in bone marrow). Since
three days she experienced progressive bilateral loss of
vision with nausea and vomiting. On admission her visu-
al acuity was 1/60 in both eyes. Fundoscopic examination
revealed bilateral serous retinal detachment and two
small peripheral retinal haemorrhages in the left eye. The
department of internal medicine was consulted to search
for potential underlying disease. She appeared ill and
anaemic, and she had icteric sclerae. Her blood pressure
was 110/60 mmHg, there was no fever, and there were no
neurological abnormalities. Laboratory studies showed a
haemoglobin concentration of 5.6 mmol/L, thrombocy-
topenia (<10×109/L), normal renal function (creatinine 73
µmol/L), and increased total bilirubin (104 µmol/L; conju-
gated bilirubin 18 µmol/lL) and lactate dehydrogenase
(3033 U/L) concentrations. The Coombs test was nega-
tive, and the M-protein concentration was 31.9 g/L. A
peripheral blood smear revealed schistocytes, and bone
marrow examination demonstrated 6% plasma cells and
an increased number of megakaryocytes. The diagnosis of
TTP was considered, and she was treated initially with
high dose glucocorticoids and transfusions of fresh frozen
plasma. Because of a rapid decline of the Hb-concentra-
tion, she received red blood cell transfusions. Daily plas-
ma exchange was started the following day. The diagno-
sis of TTP was confirmed later by ADAMTS13 activity
levels that fell below 5%. Plasma exchange therapy
induced a rapid increase in thrombocytes, haemoglobin,
and ADAMTS13 activity (Figure 1). The frequency of
plasma exchange was tapered after ten days and stopped
twenty days after the first day of treatment. Three weeks
after initial presentation, all laboratory values had
returned to normal, and ADAMTS13 activity had
increased to 57%. Both eyes showed complete retinal re-
attachment without fundoscopic abnormalities, and visu-
al acuity had increased to 1.0 in both eyes. She stayed in
complete remission, despite the recurrence of the M-com-
ponent (Figure 1). 
Design and methods
ADAMTS13 activity was determined using a collagen
binding assay (CBA) of degraded VWF essentially as
described previously.6 Levels of ADAMTS13 activity in
normal individuals range from 28-119% whereas
ADAMTS13 activity levels are < 5% in patients with
acquired or congenital TTP.6 Levels of anti-ADAMTS13
antibodies in plasma were measured using Technozym
inhibitor ELISA (Technoclone, Vienna, Austria) according
to the instructions provided by the manufacturer. Values
of > 15 U/mL were considered to reflect the presence of
anti-ADAMTS13 antibodies in accordance with the
instructions provided by the manufacturer. The
ADAMTS13 antibody assay has produced very high val-
ues in occasional individuals without TTP or severe
ADAMTS13 deficiency.7 To confirm the presence of anti-
bodies to ADAMTS13, we assessed the binding of
patient-derived antibodies to a panel of recombinant
ADAMTS13 fragments, essentially as described previous-
ly.4 Total immunoglobulins (IgG) were purified from plas-
ma of the patient using protein G affinity chromatography
(Amersham Biosciences, Uppsala, Sweden). Using gel
electrophoresis, partial purification of the M-protein was
performed by excision of the band (without immune fix-
ation) from the electrophoresis gel and subsequent diffu-
sion of the M-protein into phosphate buffered saline
(PBS). After this procedure 7.7% kappa immunoglobulins
and 92.3% lambda immunoglobulins were found. Thus,
Figure 1. Plasma concentrations of thrombocytes and
immunoglobulins, and ADAMTS13 activity. The course of the num-
ber of circulating thrombocytes (open circles), plasma
immunoglobulin concentration (filled squares), and activity of
ADAMTS13 (open triangles) in time (days after first plasma
exchange).
taking into account the normal kappa/lambda distribution
of 2/1, there was 88.4% M-protein in the sample and
11.6% polyclonal immunoglobulins. To determine the
effect of the isolated immunoglobulins on FRETS-VWF73
substrate (Peptides International, Louisville, KY, USA)
cleavage by plasma ADAMTS13, thorough dialysis was
required to remove all traces of salts and buffer compo-
nents. IgG purified from normal pooled plasme (NHP)
was included as control. Purified IgG was pre-incubated
for 1 hour with NHP, prior to the addition of FRETS-
VWF73 substrate and start of measurement. Residual
ADAMTS13 activity was calculated as described previ-
ously.8 Binding of immunoglobulins to ADAMTS13 was
determined using a modification of the Technozym
inhibitor ELISA; instead of serial plasma dilutions, several
dilutions of IgG in incubation buffer were used. 
Results and Discussion
Our patient presented with subacute loss of vision due
to bilateral serous retinal detachment. This is a rare ocu-
lar complication of TTP, which can develop, mostly late,
in the course of the disease.9-11 Retinal detachment is
thought to occur due to localized ischaemic injury to the
retinal pigment epithelium, caused by microthrombi in
the small choroidal vessels, which inhibits adequate trans-
port of fluid from the subretinal space.11 Our patient
regained complete vision by treatment with plasma
exchange therapy.
We found that ADAMTS13 activity was undetectable
in plasma. Anti-ADAMTS13 antibody levels were high
(1632 U/mL). Because our patient had a history of a
benign monoclonal gammopathy, we hypothesized that
the M-protein might be directed against ADAMTS13. It is
known that M-proteins can possess antibody activity,12
but M-proteins directed against ADAMTS13 have never
been described, although the possibility has been postu-
lated in 1991, when the pathophysiology of TTP was not
yet elucidated.13 We isolated the M-protein to determine
whether this immunoglobulin was directed against
ADAMTS13. The isolated M-protein, at a concentration
of 50 µg/mL did not inhibit VWF-cleavage activity of
ADAMTS13 in a FRETS-VWF73 assay, whereas 400
µg/ml of total IgG inhibited ADAMTS13 activity with
approximately 40% (data not shown). Binding assays
demonstrated that the isolated M-protein did not bind to
ADAMTS13, in contrast to total IgG purified from plasma
of the patient (Figure 2). This experiment demonstrates
that in this patient the M-protein is not involved in the
pathogenesis of the TTP. 
In most patients with acquired TTP, circulating anti-
ADAMTS13 antibodies are present that neutralize
ADAMTS13 activity. Recently, it was demonstrated that
in all presently characterized patients with anti-
ADAMTS13 antibodies, these antibodies are directed
against the cysteine-rich/spacer domains.2-5 To confirm
the presence of anti-ADAMTS13 antibodies we deter-
mined the binding of patient derived IgG with a series of
recombinant ADAMTS13 fragments. These experiments
revealed predominant binding of antibodies to the car-
boxy-terminal CUB1-2 domains. In addition, less promi-
nent, but significant binding to a fragment containing the
disintegrin/TSR1/cysteine-rich/spacer domains was
observed (Figure 3). Antibodies directed towards the CUB
domains have previously been observed by Klaus et al.3
The CUB domains are dispensable for VWF cleavage
activity in vitro (2;14), although in vivo the CUB-1
domain may serve as the docking site for ADAMTS13 to
bind unusually large VWF under flow.15 Alternatively,
antibodies directed towards the CUB domains may accel-
erate clearance of ADAMTS13 from the circulation.16
Further studies are needed to determine whether antibod-
ies directed towards the CUB domains of ADAMTS13
contribute to the pathogenesis of acquired TTP. 
In summary, we report a patient with MGUS, with
bilateral serous retinal detachment as the first presenting
sign of TTP, and we studied the possible relationship
between these conditions. The study emphasizes that
ocular symptoms may be the first sign of TTP and that
early diagnosis and treatment can induce complete recov-
ery of vision. In addition, we demonstrated that MGUS
and TTP can co-exist in one patient as distinct pathophys-
iological entities. 
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Figure 2. Binding of IgG to ADAMTS13. Binding of the isolated M-
protein (open squares), total IgG purified from plasma of the
patient (open triangles), and IgG purified from NHP (open circles),
to immobilized ADAMTS13. 
Figure 3. Epitope-mapping of anti-ADAMTS13 antibodies by
immuno precipitation. Antibodies present in 30 µL of plasma of
the patient (p) were immobilized on protein G sepharose and incu-
bated with recombinant ADAMTS13 protein fragments. Antibodies
present in 30 µL of NHP were included as negative control (-), as
a positive control a monoclonal antibody directed against the c-
terminal V5-tag on the recombinant fragments was included (+).
ADAMTS13 fragments that bound specifically to the immobilized
antibodies were detected on immunoblot.
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